June 11, 2020
|
Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
|
June 9, 2020
|
Outlook Therapeutics to Present at the Virtual Investor Fireside Chat Series
|
|
June 3, 2020
|
Outlook Therapeutics Announces Closing of $16.0 Million Private Placement
|
|
May 26, 2020
|
Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
|
|
May 15, 2020
|
Outlook Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2020 and Provides Corporate Update
|
|
April 21, 2020
|
Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors
|
|
April 15, 2020
|
Outlook Therapeutics to Present at the April 2020 Virtual Investor Summit
|
|
April 14, 2020
|
Outlook Therapeutics Provides COVID-19 Impact Update on Ongoing Clinical Trials NORSE 1 and NORSE 2
|
|
March 5, 2020
|
Outlook Therapeutics Announces LYTENAVA™ (bevacizumab-vikg), Anticipated Brand Name for ONS-5010, If Approved
|
|
February 26, 2020
|
Outlook Therapeutics Announces Closing of $10.2 Million Financings Priced At-The-Market
|
|